Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

• Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs
• With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation
• In a recent announcement, the company reported the successful completion of its Phase I clinical trial, which showed that the drug was safe and well tolerated
• Odyssey is looking to present the findings of the Phase I study to the FDA and is also preparing for the planned Phase II trial

A soft and squishy organ that can be deformed with a simple touch, the human brain is extremely sensitive. And although it is encased in a sturdy skull and surrounded by a cushioning fluid that collectively work to protect it from the external environment and forces that could easily wreak havoc, it is still vulnerable to extremities. In fact, blows, jolts, violent shaking, or rapid decelerations as a result of an accident, for example, can and do override these protections, leading to a mild form of brain injury called mTBI or concussion or mTBI, an area of interest for medical company Odyssey Health (OTC: ODYY).

Concussion Effects

After a concussion, and depending on the concussed individual, the brain undergoes changes triggered by, among others, mechanical damage to neuronal connections, chemical imbalance, and activation of inflammation-inducing immune cells (https://ibn.fm/L7YoI), which cause such harmful responses as…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.